Regression of lymphomatous skin deposits in a chronic lymphocytic leukemia patient treated with the Toll-like receptor-7/8 agonist, imiquimod

Leukemia and Lymphoma

Volumn 46, Issue 6, 2005, Pages 935-939

  Spaner, David E ^a,b,c   Miller, Richard L ^d   Mena, Jenny ^a   Grossman, Larry ^e   Sorrenti, Vicki ^b   Shi, Yonghong ^a  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d 3M Pharmaceuticals   (United States)

^e SCARBOROUGH HOSPITAL   (Canada)

Author keywords

Cancer vaccines; Chronic lymphocytic leukemia; Costimulatory molecules; Human; Toll like receptors; Tumor immunity

Indexed keywords

IMIDAZOQUINOLINE DERIVATIVE; IMIQUIMOD; LIQUID NITROGEN; S 26424; S 28690; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; UNCLASSIFIED DRUG;

AGED; ARTICLE; B CELL LYMPHOMA; CANCER IMMUNOTHERAPY; CASE REPORT; CHRONIC LYMPHATIC LEUKEMIA; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIDE EFFECT; SIGNAL TRANSDUCTION; SKIN DEFECT; SKIN LYMPHOMA; TUMOR CELL; TUMOR REGRESSION;

AGED; AMINOQUINOLINES; ANTINEOPLASTIC AGENTS; DISEASE PROGRESSION; HUMANS; IMMUNOTHERAPY; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA; MALE; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; TOLL-LIKE RECEPTOR 7; TOLL-LIKE RECEPTOR 8; TREATMENT OUTCOME;

EID: 21844442818     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/10428190500054426     Document Type: Article

References (12)

1. Cheson BD, Bennett JM, Grever M et al. NCIC-sponsored working group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996;87:4990-4997.
2. Gitelson E, Hammond C, Mena J et al. CLL-reactive T cells during tumor progression and after oxidized autologous tumor cell vaccines. Clin Cancer Res 2003;9:1656-1665.
3. Spaner D. Amplifying cancer vaccine responses by modifying pathogenic gene programs in tumor cells. J Leukoc Biol 2004;76:338-351.
4. Hemmi H, Kaisho T, Takeuchi O et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 2002;3:196-200.
5. Garland SM. Imiquimod. Curr Opin Infect Dis 2003;16:85-89.
6. Miller RL, Gerster JF, Owens ML, Slade HB, Tomai MA. Imiquimod applied topically: a novel immune response modifier and new class of drug. Int J Immunopharmacol 1999;21:1-14.
7. Spaner D, Raju K, Radvanyi L, Lin Y, Miller RG. A role for perforin in activation-induced cell death. J Immunol 1998;160:2655-2664.
8. Bernasconi NL, Onai N, Lanzavecchia A. A role for Toll-like receptors in acquired immunity: up-regulation of TLR9 by BCR triggering in naive B cells and constitutive expression in memory B cells. Blood 2003;101:4500-4504.
9. Hart DN. Dendritic cells: unique leukocyte populations which control the primary immune response. Blood 1997;90:3245-3287.
10. Ugurel S, Wagner A, Pfohler C, Tilgen W, Reinhold U. Topical imiquimod eradicates skin metastases of malignant melanoma but fails to prevent rapid lymphogenous metastatic spread. Br J Dermatol 2002;147:621-624.
11. Savage P, Horton V, Moore J, Owens M, Witt P, Gore ME. A phase I trial of imiquimod, an oral interferon inducer, administered daily. Br J Cancer 1996;74:1482-1486.
12. Furman RR, Asgary Z, Mascarenhas JO, Liou HC, Schattner EJ. Modulation of NF-kappa B activity and apoptosis in CLL B cells. J Immunol 2000;164:2200-2206.